Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTTP | P55157 | 15/20 | 0.52 |
| ▸ | APOB | P04114 | 9/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | SMO | Q99835 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7038094 | 0.87 | MTTP (0.46) | MTTPAPOBKDM4EGAAMAPT | |
| SCHEMBL6278519 | 0.86 | MTTP (0.55) | MTTPAPOBKDM4EALDH1A1LMNA | |
| SCHEMBL6675345 | 0.85 | MTTP (0.49) | MTTPAPOBKDM4EGAA | |
| SCHEMBL7042958 | 0.84 | MTTP (0.53) | MTTPAPOBKDM4ESMOALDH1A1 | |
| SCHEMBL7043465 | 0.84 | MTTP (0.49) | MTTPAPOBGAA | |
| SCHEMBL6673912 | 0.80 | MTTP (0.47) | MTTPAPOBKDM4EGAA | |
| SCHEMBL7043296 | 0.79 | MTTP (0.57) | MTTPAPOBGAA | |
| SCHEMBL31393757 | 0.78 | CHRNB2 (0.71) | MTTPAPOBALDH1A1GAA | |
| SCHEMBL6255815 | 0.78 | MTTP (0.53) | MTTPAPOBKDM4EALDH1A1LMNA | |
| SCHEMBL7042911 | 0.77 | MTTP (0.50) | MTTPAPOBKDM4ESMOALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1465613-A2 | COMBINATION OF MTP INHIBITORS OR APOB SECRETION INHIBITORS WITH FIBRATES FOR USE AS DRUGS | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2004-10-13 | — | — | EP | disclosed |
| US-20030162788-A1 | Combination of MTP inhibitors or apoB-secretion inhibitors with fibrates for use as pharmaceuticals | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-08-28 | — | — | US | disclosed |
| WO-2003057205-A2 | COMBINATION OF MTP INHIBITORS OR APOB SECRETION INHIBITORS WITH FIBRATES FOR USE AS DRUGS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-07-17 | — | — | WO | disclosed |
| US-20030073836-A1 | Heteroarylcarboxylic acid amides, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-04-17 | — | — | US | disclosed |
| WO-2003004020-A1 | HETEROARYL CARBOXYLIC ACID AMIDES, THE PRODUCTION THEREOF AND THE USE OF THE SAME AS INHIBITORS OF THE MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN (MTP) | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162788-A1 | Combination of MTP inhibitors or apoB-secretion inhibitors with fibrates for use as pharmaceuticals | APOB, LIPC, MTPN | MTTP 9/4885APOB 1/4885KDM4E 4449/4885 |
| US-20030073836-A1 | Heteroarylcarboxylic acid amides, the preparation thereof and their use as pharmaceutical compositions | MTTP, CETP, CES1 | MTTP 1/4885APOB 18/4885KDM4E 1812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.